Skip to main content


Figure 6 | Breast Cancer Research

Figure 6

From: QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

Figure 6

Levels of secreted VEGF were measured in LCC6, LCC6Her2, MCF-7, and MCF-7Her2 cells after treatment with a singles dose of QLT0267, docetaxel, or a combination of QLT0267 and docetaxel. LCC6, LCC6Her2, MCF-7, and MCF-7Her2 were treated with 267 (10 μM), Dt (0.25 nM) or a combination of both for 72 hours. Conditioned media was collected subsequently assessed for vascular endothelial growth factor (VEGF) secretions using ELISA as described in the Materials and methods. All four cell lines assessed showed a decrease in VEGF secretion when treated with low doses of QLT0267 (267) alone or with the combination 267/docetaxel (Dt). Dt also moderately attenuated VEGF secretion in each cell line (n = 3).

Back to article page